Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples